Internal Medicine, Endocrinology, Diabetes, & Metabolism · San Jose, CA
NPI
1801813720
Since 2006
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
0
Medicare group memberships
Hospitals
3
Hospital affiliations
2690 S White Rd Ste 50
San Jose, CA, 95148
Phone (408) 223-7000
Medicare paid, 2024
$1.9M
112,619 services
Medicare patients, 2024
2,206
Average age 75
Drug cost, 2024
$8.8M
14,843 prescriptions
Company payments, 2025
$180K
From 41 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Joselito C Cabaccan was code J3111 (injection, romosozumab-aqqg, 1 mg), 61,324 times for 58 patients. In total Joselito C Cabaccan billed 112,619 services in 61 codes, and Medicare paid $1.9M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2023-11-11.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J3111 Injection, romosozumab-aqqg, 1 mg | Office | 61,324 | 58 | $8.13 | $499K |
| J0897 Injection, denosumab, 1 mg | Office | 15,661 | 174 | $19.51 | $306K |
| 99214 Office E&M - Established | Office | 3,663 | 1,515 | $98.94 | $362K |
| 82962 Clinical Chemistry | Office | 2,362 | 992 | $3.21 | $7,582 |
| 36415 Venipuncture Blood Collection | Office | 2,328 | 1,157 | $8.65 | $20K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 2,231 | 1,285 | $13.22 | $29K |
| 99213 Office E&M - Established | Office | 2,084 | 1,270 | $70.13 | $146K |
| 83036 Blood Count | Office | 1,893 | 852 | $9.52 | $18K |
| 84443 Clinical Chemistry | Office | 1,481 | 854 | $16.46 | $24K |
| 84439 Clinical Chemistry | Office | 1,462 | 849 | $8.84 | $13K |
| 83970 Clinical Chemistry | Office | 1,165 | 604 | $40.45 | $47K |
| 82306 Clinical Chemistry | Office | 1,130 | 603 | $29.01 | $33K |
| 96372 Injection Administration | Office | 787 | 293 | $12.15 | $9,560 |
| 82043 Clinical Chemistry | Office | 675 | 482 | $5.66 | $3,821 |
| 82570 Clinical Chemistry | Office | 661 | 471 | $5.08 | $3,358 |
By year: 2022 $1.5M for 93,128 services; 2023 $1.7M for 105,008 services; 2024 $1.9M for 112,619 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 82962 Clinical Chemistry | 2,362 | 992 | $3.21 | $7,582 |
| 36415 Venipuncture Blood Collection | 2,328 | 1,157 | $8.65 | $20K |
| 83036 Blood Count | 1,893 | 852 | $9.52 | $18K |
| 84443 Clinical Chemistry | 1,481 | 854 | $16.46 | $24K |
| 84439 Clinical Chemistry | 1,462 | 849 | $8.84 | $13K |
| 83970 Clinical Chemistry | 1,165 | 604 | $40.45 | $47K |
| 82306 Clinical Chemistry | 1,130 | 603 | $29.01 | $33K |
| 82043 Clinical Chemistry | 675 | 482 | $5.66 | $3,821 |
| 82570 Clinical Chemistry | 661 | 471 | $5.08 | $3,358 |
| 81002 Clinical Chemistry | 559 | 390 | $3.41 | $1,906 |
Medicare prescription drug claims, 2024
In 2024, the drug Joselito C Cabaccan prescribed most often to Medicare patients was Levothyroxine Sodium, with 1,218 prescriptions and refills. In total Joselito C Cabaccan wrote 14,843 Medicare prescriptions that cost $8.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levothyroxine Sodium Generic | 1,218 | 3,444 | 356 | $20K |
| Ozempic Semaglutide | 1,000 | 1,721 | 267 | $1.6M |
| Jardiance Empagliflozin | 885 | 1,975 | 277 | $1.1M |
| Metformin Hcl Generic | 719 | 2,058 | 239 | $6,728 |
| Trulicity Dulaglutide | 654 | 994 | 148 | $949K |
| Mounjaro Tirzepatide | 507 | 683 | 103 | $702K |
| Repaglinide Generic | 486 | 1,330 | 172 | $24K |
| Atorvastatin Calcium Generic | 478 | 1,378 | 164 | $5,474 |
| Losartan Potassium Generic | 441 | 1,272 | 150 | $4,248 |
| Amlodipine Besylate Generic | 413 | 1,221 | 149 | $3,147 |
| Metformin Hcl Er Metformin Hcl | 379 | 1,063 | 128 | $5,266 |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 372 | 973 | 151 | $54K |
| Farxiga Dapagliflozin Propanediol | 371 | 782 | 106 | $414K |
| Synthroid Levothyroxine Sodium | 312 | 868 | 89 | $33K |
| Pioglitazone Hcl Generic | 304 | 890 | 104 | $4,042 |
Brand drugs: 7,097 claims; generic drugs: 6,986 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Joselito C Cabaccan $180K ($180K in general payments such as food, travel and fees) from 41 companies. The largest payer was Lilly USA, LLC with $52K.
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC LLY | 85 | $52K |
| Novo Nordisk Inc NVO | 53 | $37K |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 51 | $33K |
| Ascendis Pharma Endocrinology Inc ASND | 21 | $24K |
| Sanofi-Aventis U.S. LLC SNY | 15 | $15K |
| Amgen Inc. AMGN | 47 | $7,331 |
| Genzyme Corporation SNY | 3 | $7,025 |
| Mannkind Corporation MNKD | 12 | $2,019 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 13 | $1,274 |
| Madrigal Pharmaceuticals MDGL | 8 | $319 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.